Radius completes $21.4m third financing tranche
The third tranche included $21.4m in equity financing from Radius’ current investors, bringing gross proceeds received to date from the $91m financing to $78.7m. The company intends to
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.